Navigation Links
University of California Los Angeles Selects Velos eResearch

FREMONT, Calif., April 23 /PRNewswire/ -- After a review of several vendors, the University of California Los Angeles (UCLA) has selected the services of Velos and its flagship product, Velos eResearch. The clinical research management system is being implemented at UCLA's Jonsson Comprehensive Cancer Center and an affiliated clinical research network, Translational Oncology Research International, (TORI). Plans are in place to deploy the system in non-cancer studies being conducted in the David Geffen School of Medicine at UCLA.

A UCLA selection committee chose Velos eResearch because the system offered the best core functionality for managing clinical trials and it was the most adaptable and user-friendly for tracking patients.

"We have a very complex structure here on campus and in the TORI Network," said Nancy Ryba, a registered nurse and director of the Jonsson Cancer Center's Clinical Research Unit. "Velos eResearch allows us to accurately track the patients and studies with the level of detail that we require. Equally important, Velos is the most user-friendly for those who work with the system. It is also the most flexible and adaptable for addressing all of our on-campus and off-campus needs."

The cancer center tracks everything from simple studies to very complex, multi-arm clinical trials that require very detailed patient information, Ryba said. The system will also be used to track studies within the TORI network, a large group of participating research sites and medical practices stretching throughout the country, as well as some international sites.

"We are pleased to be selected and to have this opportunity to serve UCLA," stated John S. McIlwain, President and CEO of Velos, Inc. "The School of Medicine and the Jonsson Comprehensive Cancer have a well-known commitment to excellence in medical research. They also have an outstanding leadership and technical team, which is so important for projects of this magnitude."

Implementation of Velos eResearch at the cancer center began through interviews with experts in clinical trials and stakeholders at the institution. It was determined that the system would first be deployed to tackle the most important business process needs of leadership and staff.

"There are so many areas that Velos eResearch is capable of addressing," said Courtney Martin, associate director of the cancer center's Informatics Division, "but we chose to start with the areas of highest need."

Improving the cancer center's ability to manage its research portfolio was foremost among the areas of highest need. With Velos eResearch, cancer center leadership know what studies are open, how well they are accruing patients and the stage they have reached in the regulatory process.

"Managing that was always a very laborious and inefficient process for us," continued Martin. "Before Velos eResearch, it was much more difficult."

Stakeholders and clinical trials experts helped cancer center leadership define other areas of focus for implementation. Senior leadership needed quick understanding of what was happening at the research staff level from those enrolling and interacting with patients. Those users are responsible for ensuring that all regulatory activities are carried out appropriately. They also are providing needed data to billers.

"Now our senior leadership will be able to log into the system and be able to access the data they need in real time," said Martin.

Billing has been an equally important priority for the cancer center. With Velos, the invoicing staff will have access in real time to the patient tracking data they need for billing. Previously, fund managers spent much of their time inefficiently retrieving the necessary data from several different locations.

"Velos will help us become more efficient in the turn-around time in processing billing for clinical trials," stated Martin.

Ryba said UCLA and the TORI network have been tracking studies and patients for nearly 13 years via paper logs and antiquated database processes.

"We look forward to moving into a system that will allow us to track studies and patients real time in an efficient manner that will facilitate coordination of our clinical trials and allow accurate financial tracking of study procedures and processes," Ryba said.

The cancer center will have the ability to electronically exchange data with the various TORI network sites. Previously, data was transmitted by email and fax and manually keyed into the old database. With the new system, the TORI sites will enter their own data directly into Velos.

"They can go online, view the studies available at their site and track their patients through Velos," Ryba said. "Eventually, protocols and informed consents will be Web-based for all studies."

Cancer center senior leadership will use accrual data in formulating NCI reports and for other regulatory functions such as the Internal Scientific Review Committee, Quality Assurance and the Data Safety Monitoring Board.

"We are closely watching progress at the cancer center," said Vikki Jenkins, MA, MPH, executive director of the Office of Clinical Trials at the David Geffen School of Medicine at UCLA. "We will no doubt apply our own perspectives and approaches when the system is implemented for non-cancer studies. In the meantime, we have enjoyed working with the Velos team and we are enthusiastic about the future."

About the Jonsson Comprehensive Cancer Center at UCLA

In the late 1960s, a group of scientists and volunteers at UCLA came together to develop a cancer center they hoped would become renowned for excellence in research, education and patient care. In 1976, the cancer center at UCLA was designated "comprehensive" by the National Cancer Institute (NCI). Of the 63 NCI cancer center programs nationwide, only 41 receive the gold-star comprehensive status. UCLA's Jonsson Comprehensive Cancer Center (JCCC) receives this honor for maintaining the highest standards of excellence in patient care, education, basic science, clinical research and cancer prevention.

JCCC has established an international reputation in a number of areas, including: Developing new cancer therapies; providing the best in experimental and traditional treatments; and expertly guiding and training the next generation of medical researchers. Numerous successful targeted therapies were developed based on basic science done in UCLA laboratories and later clinical research with UCLA patients. A few of the more well-known therapies include: Herceptin, a targeted breast cancer drug and the first approved treatment that attacks cancer at its genetic root; Gleevec, a once-a-day pill that targets a common form of adult leukemia called chronic myelogenous leukemia, or CML; Sprycel, also a pill that targets CML; Tarceva, a targeted lung cancer drug; and Avastin, a targeted drug for colorectal cancer, lung cancer and breast cancer.

With a membership of more than 350 physicians and scientists, JCCC is one of the largest comprehensive cancer centers in the nation, handling more than 20,000 patient visits per year and conducting hundreds of clinical trials, providing the latest in experimental cancer treatments.

About David Geffen School of Medicine at UCLA

The David Geffen School of Medicine is an internationally recognized leader in research, medical education, and patient care. In 2002 Mr. David Geffen announced a $200 million unrestricted endowment for the school and the school thus was named. The endowment enables the school to compete in perpetuity with the finest medical institutions in the world for outstanding faculty regardless of the economic climate, to provide critical financial support to enroll the finest students regardless of need, and to develop forward-looking research and clinical programs.

The medical school today has more than 2,000 full-time faculty members, almost 1,300 residents, more than 750 medical students and almost 400 Ph.D. candidates. The UCLA Medical Center has been ranked "Best in the West" by U.S. News and World Report's annual survey of the best hospitals in America for fourteen consecutive years. The medical school is ranked ninth in the country in research funding from the National Institutes of Health and third in the United States in research dollars from all sources.

About Velos

Velos, Inc. is the recognized leader and trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S. Its customers include 21 of the top 25 academic medical centers and research institutions. Among the 100 largest recipients of NIH clinical research funding, Velos customers receive over 50 percent of such NIH extramural funding.

Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. The system fundamentally improves the way data is collected, organized and shared. A pure Internet technology platform, Velos eResearch harnesses the Internet to enable research sites, sponsors, and patients to collaborate in a secure, integrated system platform. System users are freed of redundant data entry and related time delays associated with most clinical research today. With emphasis on workflow and integration, Velos addresses the clinical, administrative and financial information needs of medical researchers. Founded in 1996, Velos is privately held with headquarters in Fremont, California. For more information, visit

This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.

SOURCE Velos, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. University of Redlands Student Cody Unser Documentary Run to Start Today in L.A.
2. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
3. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
4. British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection
5. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
6. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
7. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
8. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
9. Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
10. American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time
11. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
Post Your Comments:
(Date:10/8/2015)... October 8, 2015 " Biomedical ... Growth, Trends and Forecast 2014 - 2022 " , ... 2.63 billion in 2013 and is anticipated to expand at ... USD 4.00 billion in 2022. --> " ... Share, Growth, Trends and Forecast 2014 - 2022 " ...
(Date:10/8/2015)... N.C. , Oct. 8, 2015  Clariant, a world ... Packaging manufacturing facility in Belen, New Mexico ... for healthcare applications, including desiccant canisters and packets ... Belen plant is the second Clariant site – ... – to meet the ISO 15378:2011 standards, following only the ...
(Date:10/8/2015)... , Oct. 8, 2015  Nektar Therapeutics (Nasdaq: ... pain and oncology portfolio during an Investor and Analyst ... p.m. Eastern Time in New York City ... of the NKTR-214 Phase 1/2 clinical program and biomarker ... cytokine designed to preferentially stimulate the production of CD8-positive ...
Breaking Medicine Technology:
... SHP ) ("ShangPharma" or the "Company"), a ... company, today announced that it will release its unaudited ... ended December 31, 2011 on March 13, 2012. Management ... at 08:00AM New York Time on March 13, 2012 ...
... 28, 2012  Based on its recent analysis of ... Brainsway with the 2012 Global Frost & Sullivan ... Magnetic Stimulation (dTMS) is the only non-invasive technique ... depression and other neuro-psychiatric disorders without causing any ...
Cached Medicine Technology:
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... ... anniversary of their “Agents of Change” program, a community improvement initiative that involves ... newest charity to benefit from the assistance of Confidence Plus Insurance is the ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the fastest ... of life to save money on the high cost of their prescription medications ... medication, individuals and families can receive their medications delivered direct from over 180 ...
(Date:10/9/2015)... ... October 09, 2015 , ... Santa Rosa Consulting and ... as MD Anderson prepares to go-live on the Epic platform in March of 2016. ... 2016. Santa Rosa will execute the contract by supporting Scheduling Appointment Conversion and the ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... counseling, recently opened its newest office in Maryland – its Bethesda ... a background as a project management technology consultant to many of the largest ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... franchise, was recognized by Cabarrus County Active Living and Parks for its outstanding ... care company’s dedication to consistently going above and beyond the call of ...
Breaking Medicine News(10 mins):
... Latest version of the "All About Me" Children,s Health Journal has just ... and keep track of their childrens, immunizations and developmental progress. It is ... coast to coast have been using it since its inception. A diaper ... ...
... Health Properties, Inc. (NYSE: NHP ) announced the tax treatment for its 2008 dividend ... COMMON STOCK (CUSIP# 638620104), 2008 ... Return Total Unrecaptured, Record ... Capital Section, Date ...
... into effect, granting children 12 years and older a ... right to access condoms. But current policies allow ... out condomspolicies that two researchers, writing in this week,s ... of the country,s youth. , Juliana Han (Harvard Law ...
... lifestyle interventions that not only modify diet and physical ... obese children lose weight and maintain that loss for ... that in adolescents the effect lasts for at least ... to behaviour change programs for adolescents may provide additional ...
... PARK, Calif., Jan. 20 Exponent, Inc. (Nasdaq: ... for the fourth quarter and fiscal year ended January 2, ... February 4, 2009. The Company will host a corresponding ... 1:30 p.m. Pacific Time. Michael Gaulke, Chairman and Chief ...
... researchers say , , TUESDAY, Jan. 20 (HealthDay News) -- ... a saliva test for monitoring type 2 diabetes, which ... first time, researchers from Oregon and India have identified ... with diabetes than in non-diabetics. Using these proteins, they ...
Cached Medicine News:
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
Medicine Products: